Global Phase 3 trial of Atea’s combo therapy doses 1st hep C patient
The first participant has been dosed in a Phase 3 clinical trial testing Atea Pharmaceuticals’ combination therapy of bemnifosbuvir and ruzasvir in people with chronic…
The first participant has been dosed in a Phase 3 clinical trial testing Atea Pharmaceuticals’ combination therapy of bemnifosbuvir and ruzasvir in people with chronic…
Astrivax Therapeutics has begun clinical testing of AVX70371, an experimental vaccine designed to treat hepatitis B. “Starting clinical development with AVX70371 is the first…
AusperBio raised $50 million to advance the development of chronic hepatitis B treatment AHB-137. The company said the funding will help it launch Phase…
People with hepatitis C in the U.S. who are insured through state Medicaid programs that require them to be sober to access treatment are…
The investigational treatment imdusiran used as part of combination therapy regimens has led to a functional cure for eight people with chronic hepatitis…
AHB-137, Ausperbio’s experimental therapy, safely and effectively suppressed the disease-causing hepatitis B virus (HBV) in people with chronic hepatitis B, according to interim…
Hepatitis Awareness Month is held every May to raise awareness about viral hepatitis, an inflammation of the liver caused by a virus, and help…
Treatment with certain types of cholesterol-lowering drugs called statins may help reduce the risk of cirrhosis, or irreversible liver scarring, liver cancer, and death in…
Increasing the levels of a protein called IRF1 helps suppress infection of the hepatitis D virus (HDV) and its growth inside of cells, a new…
Patients, caregivers, and supporters will head to Washington later this month to advocate for policies to improve life for people living with fatty liver…